Feb 7 (Reuters) - Eli Lilly and Co LLY.N:
MOST PATIENTS ON LILLY'S OMVOH® (MIRIKIZUMAB-MRKZ) FOR CROHN'S DISEASE ACHIEVED SUSTAINED CLINICAL REMISSION AND ENDOSCOPIC RESPONSE AT TWO YEARS
ELI LILLY AND CO - NEARLY 90% OF PATIENTS SUSTAIN ENDOSCOPIC RESPONSE AT TWO YEARS
Source text: ID:nPnbZkPwFa
Further company coverage: LLY.N